Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This evidence concerns the gene MTOR and digestive system neuroendocrine tumor, grade 1/2.